In community pharmacy, dispensing and monitoring anticoagulated patients is one of our most critical responsibilities. Understanding the specific characteristics of Direct Oral Anticoagulants (DOACs) versus the classic acenocoumarol (Sintrom) is essential to ensure adherence and minimise risks.
The final decision on anticoagulant treatment always rests with the prescribing doctor. Our role as pharmacists is to inform, educate, and detect potential medication-related problems.
The Legacy of Acenocoumarol (Sintrom): Advantages and Challenges
Acenocoumarol, commonly marketed as Sintrom, has been the cornerstone of oral anticoagulant treatment for decades. Its mechanism of action, based on the inhibition of vitamin K epoxide reductase, reduces the synthesis of vitamin K-dependent coagulation factors. This makes it an effective drug, but with a narrow therapeutic window and high interindividual variability.
The main challenge with acenocoumarol is the need for rigorous INR (International Normalized Ratio) control, which must be maintained within a specific therapeutic range to prevent both thrombotic and haemorrhagic events. Factors such as diet (foods rich in vitamin K), drug interactions (antibiotics, NSAIDs, etc.), and the patient's health status can significantly alter the INR, requiring frequent dose adjustments. The Spanish Agency of Medicines and Medical Devices (AEMPS) offers detailed technical data sheets that highlight these interactions. (Readers should check with their own national regulator for regulatory information).
The DOAC Revolution: Simplifying Anticoagulation
Direct Oral Anticoagulants (DOACs) represent a significant advance in anticoagulation. They include direct factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) and direct thrombin inhibitors (dabigatran). Their main advantage lies in their more predictable pharmacokinetics and pharmacodynamics, which eliminates the need for routine INR monitoring.
This characteristic greatly simplifies patient management, improving therapeutic adherence and quality of life. DOACs have proven to be at least as effective as acenocoumarol in preventing thromboembolic events in indications such as non-valvular atrial fibrillation and the treatment of deep vein thrombosis and pulmonary embolism, with a comparable or even superior safety profile in some aspects, especially in reducing intracranial haemorrhages. For more information on their use, the guidelines of the Spanish Society of Clinical, Family and Community Pharmacy (SEFAC) can be consulted. (Readers should check with their own national professional bodies for clinical guidance).
Key Considerations for the Pharmacist
As pharmacists, our work is crucial in patient education and the detection of potential problems. When dispensing DOACs, we must remember the importance of strict adherence to the regimen, as their shorter half-life means that missing a dose can have a greater impact than with acenocoumarol. It is essential to remind patients that they should not stop treatment without consulting their doctor.
In the case of acenocoumarol, education on diet and drug interactions remains paramount. We should always ask about new medications, supplements, or changes in diet. The Vademecum database is an indispensable tool for checking interactions. Furthermore, polypharmacy management is a fundamental pillar in the care of these patients.
Management of Special Situations and Pharmacovigilance
Both types of anticoagulants require precautions in special situations such as surgery, invasive procedures, or haemorrhages. It is vital that the patient informs all healthcare professionals about their anticoagulant treatment. In the event of severe haemorrhage, DOACs have specific antidotes (idarucizumab for dabigatran, andexanet alfa for rivaroxaban and apixaban), which represents a significant advantage over acenocoumarol, whose antidote is vitamin K (with a slower onset of action) or prothrombin complex concentrates.
Pharmacovigilance is a fundamental pillar. Any suspected adverse reaction, especially haemorrhages, must be reported. The European Medicines Agency (EMA) and the pharmacovigilance bulletins from the Spanish AEMPS are updated sources of information on the safety of these drugs. Our role in improving therapeutic adherence is key to the success of the treatment.
Always remember to advise the patient on the importance of carrying an anticoagulant card and informing any healthcare professional about their medication.
Frequently Asked Questions about Oral Anticoagulants
Yes, it is possible, but always under strict medical supervision. The transition process requires careful management to avoid periods of under- or over-anticoagulation. The doctor will determine the timing and method of the switch, based on the patient's INR and the chosen DOAC.
It is essential to ask about adherence (if they are taking all doses), the appearance of any signs of bleeding (bruising, gum bleeding, dark urine) or thrombosis (pain or swelling in a leg), and if they have started any other medication or supplement. It is also important to remind them that they should not stop the treatment on their own.
Unlike acenocoumarol, DOACs have very few food interactions. However, it is always prudent to advise a balanced diet and avoid drastic changes. Some drug interactions with potent inducers or inhibitors of CYP3A4 or P-glycoprotein may be relevant, so concomitant medication should always be reviewed.
Do you want to delve deeper into pharmaceutical care for polymedicated patients? Discover how to optimise follow-up and improve safety.
Explore the MDS ServiceDo you want to calculate your salary?
Use our free employment calculators with data from the 2026 Pharmacy Collective Agreement.
Calculate my salary